Improving surgical guidance for head and neck tumor treatment
Official title: Multiparametric Imaging-based Intraoperative Navigation for Guidance of Surgical Resection and Postoperative Radiotherapy in Patients With Head-and-neck Tumors - NAVIGATORR
Run by University Hospital Heidelberg · NCT05671458 · Data updated 2026-11-12
This study is testing a new way to help doctors remove head and neck tumors more accurately during surgery to improve treatment for patients with certain types of cancer.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | University Hospital Heidelberg Academic / other |
| Drugs / interventions | immunotherapy, radiation |
| Locations | 1 site (Heidelberg) |
| Status | Recruiting |
| Started | January 1, 2023 |
| Main results expected | January 1, 2027 |
| Study ends | January 1, 2027 |
| Registry record updated | January 12, 2026 |
| Trial ID | NCT05671458 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with specific types of head and neck malignancies requiring surgical resection and likely needing postoperative radiotherapy.
✕Probably not a fit
Patients who are contraindicated for radiotherapy or those who refuse to participate in the study may not benefit from this trial.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This trial aims to enhance local tumor control in head-and-neck cancer by utilizing multiparametric imaging for precise surgical resection and tailored postoperative radiotherapy. It focuses on patients with squamous cell carcinomas and salivary gland carcinomas, who are undergoing surgical treatment. The approach involves intraoperative navigation and the creation of tumor resection maps to improve surgical outcomes. The study seeks to personalize treatment strategies based on individual tumor characteristics.
Why it matters
Potential benefit: If successful, this approach could lead to better surgical outcomes and improved control of head and neck tumors.
How similar studies have gone: While this approach is innovative, similar studies have shown promise in improving surgical precision and outcomes in oncology.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of a malignancy (squamous cell carcinoma (SCC), adenocarcinoma (AC), mucoepidermoid carcinoma (MEC), adenoidcystic carcinoma (ACC)) of the midface, upper jaw and skull-base (e.g. based on imaging-studies and/or biopsies) * Indication of surgical tumor resection according to multidisciplinary tumor conference * Probably indication for postoperative radiotherapy (e.g. T3/4 tumor) * Medical operability and written informed consent of the patient to undergo surgical resection (as indicated clinically) * Patient age ≥ 18 years * Karnofsky performance index ≥ 60% * For women with childbearing potential: adequate contraception * Ability of subject to understand character and individual consequences of the trial * Written informed consent to participate in this trial Exclusion Criteria: * Contraindications against radiotherapy, especially pregnant or lactating women * Refusal of the patient to take part in the study * Participation in another competing clinical study or observation period of competing trials
Where it's running
-
Department of Radiotherapy, University of Heidelberg
Heidelberg, Germany Recruiting
Study contacts
- Study coordinator: Sebastian Regnery, PD Dr.
- Email: sebastian.regnery@med.uni-heidelberg.de
- Phone: +49 6221 56 8202
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
SI-B036 in head and neck and other solid tumors: a first-in-human study
This early-phase study tests SI-B036 in adults with locally advanced or metastatic head and neck cancers and other solid tumors to see if it is safe and tolerable, and to get initial clues about its activity.
-
LRRC15-targeted PET imaging for more precise diagnosis and staging of pancreatic, breast, lung, sarcoma and head-and-neck cancers
This project tests whether an LRRC15-targeted PET scan can better detect and stage LRRC15-expressing cancers and measures how the tracer behaves in healthy adults.
-
Understanding metal elements in radiation-induced mouth sores
This study is trying to see if certain metal elements in the body can help predict how severe mouth sores will be for patients getting radiation treatment for head and neck cancer.
-
Understanding how mutant p53/YAP proteins affect treatment resistance in head and neck cancer
This study looks at how changes in certain proteins in head and neck cancer cells might make them resistant to treatment, helping doctors find better ways to fight the disease.
-
Using breath analysis to predict mouth sores from radiotherapy in head and neck cancer patients
This study is testing whether analyzing breath samples can help predict mouth sores in head and neck cancer patients receiving radiotherapy.
-
Targeted alpha therapy [212Pb]VMT-Alpha-NET for SSTR-positive metastatic or inoperable GI neuroendocrine, pheochromocytoma/paraganglioma, small cell lung, kidney, and head & neck cancers
This trial will try an experimental targeted alpha-particle drug called [212Pb]VMT-Alpha-NET in adults whose metastatic or inoperable tumors show somatostatin receptor (SSTR) expression.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.